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We read with interest the observational study by Paula
Ramirez et al. [1] discovering the appropriate starting
time of antibiotic treatment in patients with ventilator-
associated pneumonia (VAP).
In that study, 440 patients receiving mechanical
ventilation were screened, but only patients with VAP
were studied, including 43 with gradual VAP and 28
with non-gradual VAP, and they suggested that early
antibiotic treatment should be applied in gradual VAP
patients.
However, in clinical practice, not all patients with
gradual VAP symptoms would finally progress to
VAP. According to a retrospective study [2], less than
10 % of the patients with nosocomial tracheobronchi-
tis (NTB), with similar criteria to gradual VAP, would
developed subsequent VAP (Tables 3 and 4 in [2]).
As it is difficult to discriminate these patients until
VAP has developed, it is crucial for clinicians to know
whether earlier antibiotic treatment would benefit
those patients with NTB but without subsequent
VAP. Besides, Nseir et al. [2] reported that antibiotic
use could not decrease the VAP incidence in patients
with NTB. Thus, whether early antibiotic treatment
will improve clinical outcome (such as VAP rate and
mortality) or will lead to deterioration of antibiotics
abuse based on the low proportion who developed
VAP in NTB patients remains unclear?
The other question is that, in this study, un-
adjusted comparisons were made between two
groups. The primary result was that, compared to
the VAP group, antibiotic treatment in the gradual
VAP group led to a higher rate of early clinical
response (p = 0.009). No significant difference was
found in hospital length of stay or mortality. These
results were similar to the former study [2]. Com-
pared to patients with gradual VAP, non-gradual
VAP may indicate stronger inflammation which we
thought to be a really important confounding factor
of clinical response time. Caution should be raised
when we interpret this outcome.
Authors’ response
Paula Ramírez and Mónica Gordón
As Dr Jiang and his colleagues expressed in their letter,
there are still many unknowns regarding infectious com-
plications in the mechanically ventilated patient.
We have focused on the study of the VAP maturation
process suffered by a significant number of ventilated
patients [1]. Our main conclusion is that trying to draw
a diagnostic line on most of the late-onset pneumonias
is only a response to an attempt to oversimplify the situ-
ation. We noted, like other authors [3], that the
introduction of an appropriate treatment even in the
absence of a complete diagnosis of VAP achieved an im-
proved prognosis in our patients. Unfortunately, our
study was not able to identify any tool that is able to
properly guide the initiation of antibiotic treatment.
We believe that, given recent results obtained in the
study of the so-called ventilator-associated tracheobron-
chitis as well as our own conclusions, it is necessary to
shift the methodology of studies on VAP. The next clin-
ical trials should be designed according to a dynamic
scheme to evaluate the efficacy and safety of different
strategies to identify the right time to start and end
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antibiotic treatment. Moreover, the chosen strategy
should also be evaluated in terms of ecological sustain-
ability (excessive selection of multi-resistant bacterial
strains) [4].
In conclusion, far from solving all the unknowns
mentioned by Jiang et al., our ultimate aim is to encour-
age experts in the field to change their approach to VAP
in a more consistent way to acheiev clinical reality.
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